NiQuitin CQ
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's UK launch of smoking cessation lozenges backed by £10 mil. (approximately $14.2 mil.) marketing campaign including £5 mil. ad campaign beginning in December, firm says. Mint-flavored lozenges contain either 2 mg or 4 mg nicotine polacrilex and launched in UK pharmacies in October. A one-week supply costs roughly $24.80. Launch could pave the way for eventual product introduction in U.S. Study finding lozenges lead to higher success rate than other nicotine-replacement therapies slated for publication in March Archives of Internal Medicine...